TRAIL and apoptosis induction by TNF-family death receptors

Tumor necrosis factor-related apoptosis-inducing ligand or Apo 2 ligand (TRAIL/Apo2L) is a member of the tumor necrosis factor (TNF) family of ligands capable of initiating apoptosis through engagement of its death receptors. TRAIL selectively induces apoptosis of a variety of tumor cells and transformed cells, but not most normal cells, and therefore has garnered intense interest as a promising agent for cancer therapy. TRAIL is expressed on different cells of the immune system and plays a role in both T-cell- and natural killer cell-mediated tumor surveillance and suppression of suppressing tumor metastasis. Some mismatch-repair-deficient tumors evade TRAIL-induced apoptosis and acquire TRAIL resistance through different mechanisms. Death receptors, members of the TNF receptor family, signal apoptosis independently of the p53 tumor-suppressor gene. TRAIL treatment in combination with chemo- or radiotherapy enhances TRAIL sensitivity or reverses TRAIL resistance by regulating the downstream effectors. Efforts to identify agents that activate death receptors or block specific effectors may improve therapeutic design. In this review, we summarize recent insights into the apoptosis-signaling pathways stimulated by TRAIL, present our current understanding of the physiological role of this ligand and the potential of its application for cancer therapy and prevention.

[1]  R. Webster.  A Molecular Whodunit , 2001, Science.

[2]  W. Cavenee,et al.  The potential of TRAIL for cancer chemotherapy , 2001, Apoptosis.

[3]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[4]  M. V. D. van den Brink,et al.  Nature's TRAIL--on a path to cancer immunotherapy. , 2003, Immunity.

[5]  M. Sporn,et al.  An Inducible Pathway for Degradation of FLIP Protein Sensitizes Tumor Cells to TRAIL-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[6]  H. Fine,et al.  Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. , 2002, Neoplasia.

[7]  M. Xiong,et al.  Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells , 2002, Oncogene.

[8]  Emad S. Alnemri,et al.  Temperature-sensitive Differential Affinity of TRAIL for Its Receptors , 2000, The Journal of Biological Chemistry.

[9]  D. Stuart,et al.  Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation , 1999, Nature Structural Biology.

[10]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[11]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[12]  Z. Ronai,et al.  Death receptors and melanoma resistance to apoptosis , 2003, Oncogene.

[13]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[14]  J. Tschopp,et al.  Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL* , 2000, The Journal of Biological Chemistry.

[15]  W. Zong,et al.  The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells , 2003, Oncogene.

[16]  J. Tschopp,et al.  Inhibition of fas death signals by FLIPs. , 1998, Current opinion in immunology.

[17]  G. Evan,et al.  Apoptosis. Till death us do part. , 2001, Science.

[18]  G. Kroemer,et al.  Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis , 2001, Oncogene.

[19]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[20]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[21]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[22]  D. Green.  Apoptotic Pathways Paper Wraps Stone Blunts Scissors , 2000, Cell.

[23]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[24]  P. Hersey,et al.  How melanoma cells evade trail-induced apoptosis , 2001, Nature Reviews Cancer.

[25]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[26]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[27]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[28]  Wafik S El-Deiry,et al.  Defining characteristics of Types I and II apoptotic cells in response to TRAIL. , 2002, Neoplasia.

[29]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[30]  L. Hood,et al.  Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. , 1997, Immunity.

[31]  T. Gura.  How TRAIL Kills Cancer Cells, But Not Normal Cells , 1997, Science.

[32]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[33]  R. K Srivastava,et al.  Pro-survival Function of Akt/Protein Kinase B in Prostate Cancer Cells , 2001, The Journal of Biological Chemistry.

[34]  John Calvin Reed,et al.  PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2 , 2003, Oncogene.

[35]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.